Incidence and comparative outcomes of periampullary cancer: A population-based analysis demonstrating improved outcomes and increased use of adjuvant therapy from 2004 to 2012

Caitlin A. Hester, Epameinondas Dogeas, Martin M Augustine, John C Mansour, Patricio M Polanco, Matthew Porembka, Sam C Wang, Herbert J. Zeh, Adam C Yopp

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background and Objectives: Periampullary adenocarcinoma (PAC) is stratified anatomically: ampullary adenocarcinoma (AA), distal cholangiocarcinoma (DCC), duodenal adenocarcinoma (DA), and pancreatic ductal adenocarcinoma (PDAC). We aimed to determine differences in incidence, prognosis, and treatment in stage-matched PAC patients in a longitudinal study. Methods: PAC patients were identified in The National Cancer Database from 2004 to 2012. Clinicopathological variables were compared between subtypes. Covariate-adjusted treatment use and OS were compared. Results: The 116 705 patients with PAC were identified: 1320 (9%) AA, 3732 (3%) DCC, 7142 (6%) DA, and 95 511 (82%) PDAC. DA, DCC, and PDAC were associated with worse survival compared with AA (hazard ratio [HR], 1.10; 95% CI, 1.1-1.1; HR, 1.50; 95% CI, 1.4-1.6, and HR, 1.90; 95% CI, 1.8-1.9). Among resected patients, DA was associated with improved survival compared with AA (HR, 0.70; 95% CI, 0.67-0.75); DCC and PDAC were associated with worse survival (HR, 1.41; 95% CI, 1.31-1.53 and HR, 2.041; 95% CI, 1.07-2.12). Resected AA, PDAC, and DA, but not DCC, demonstrated significantly improved survival over the studied period. While all patients had increased adjuvant therapy (AT) receipt over time (P < 0.001), only patients with PDAC had increased neoadjuvant therapy (NAT) receipt (P < 0.001). Conclusion: Resected PDAC, AA, and DA were associated with clinically significant improved survival over time, mirroring a concurrent associated increased receipt of AT.

Original languageEnglish (US)
JournalJournal of Surgical Oncology
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Adenocarcinoma
Incidence
Population
Neoplasms
Therapeutics
Cholangiocarcinoma
Survival
Neoadjuvant Therapy

Keywords

  • adjuvant therapy
  • ampullary
  • distal cholangiocarcionma
  • duodenal
  • longitudinal
  • pancreatic
  • periampullary

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

@article{6e94fb0a68254af9ab28b749f64ccb11,
title = "Incidence and comparative outcomes of periampullary cancer: A population-based analysis demonstrating improved outcomes and increased use of adjuvant therapy from 2004 to 2012",
abstract = "Background and Objectives: Periampullary adenocarcinoma (PAC) is stratified anatomically: ampullary adenocarcinoma (AA), distal cholangiocarcinoma (DCC), duodenal adenocarcinoma (DA), and pancreatic ductal adenocarcinoma (PDAC). We aimed to determine differences in incidence, prognosis, and treatment in stage-matched PAC patients in a longitudinal study. Methods: PAC patients were identified in The National Cancer Database from 2004 to 2012. Clinicopathological variables were compared between subtypes. Covariate-adjusted treatment use and OS were compared. Results: The 116 705 patients with PAC were identified: 1320 (9{\%}) AA, 3732 (3{\%}) DCC, 7142 (6{\%}) DA, and 95 511 (82{\%}) PDAC. DA, DCC, and PDAC were associated with worse survival compared with AA (hazard ratio [HR], 1.10; 95{\%} CI, 1.1-1.1; HR, 1.50; 95{\%} CI, 1.4-1.6, and HR, 1.90; 95{\%} CI, 1.8-1.9). Among resected patients, DA was associated with improved survival compared with AA (HR, 0.70; 95{\%} CI, 0.67-0.75); DCC and PDAC were associated with worse survival (HR, 1.41; 95{\%} CI, 1.31-1.53 and HR, 2.041; 95{\%} CI, 1.07-2.12). Resected AA, PDAC, and DA, but not DCC, demonstrated significantly improved survival over the studied period. While all patients had increased adjuvant therapy (AT) receipt over time (P < 0.001), only patients with PDAC had increased neoadjuvant therapy (NAT) receipt (P < 0.001). Conclusion: Resected PDAC, AA, and DA were associated with clinically significant improved survival over time, mirroring a concurrent associated increased receipt of AT.",
keywords = "adjuvant therapy, ampullary, distal cholangiocarcionma, duodenal, longitudinal, pancreatic, periampullary",
author = "{A. Hester}, Caitlin and Epameinondas Dogeas and Augustine, {Martin M} and Mansour, {John C} and Polanco, {Patricio M} and Matthew Porembka and Wang, {Sam C} and Zeh, {Herbert J.} and Yopp, {Adam C}",
year = "2018",
month = "1",
day = "1",
doi = "10.1002/jso.25336",
language = "English (US)",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",

}

TY - JOUR

T1 - Incidence and comparative outcomes of periampullary cancer

T2 - A population-based analysis demonstrating improved outcomes and increased use of adjuvant therapy from 2004 to 2012

AU - A. Hester, Caitlin

AU - Dogeas, Epameinondas

AU - Augustine, Martin M

AU - Mansour, John C

AU - Polanco, Patricio M

AU - Porembka, Matthew

AU - Wang, Sam C

AU - Zeh, Herbert J.

AU - Yopp, Adam C

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background and Objectives: Periampullary adenocarcinoma (PAC) is stratified anatomically: ampullary adenocarcinoma (AA), distal cholangiocarcinoma (DCC), duodenal adenocarcinoma (DA), and pancreatic ductal adenocarcinoma (PDAC). We aimed to determine differences in incidence, prognosis, and treatment in stage-matched PAC patients in a longitudinal study. Methods: PAC patients were identified in The National Cancer Database from 2004 to 2012. Clinicopathological variables were compared between subtypes. Covariate-adjusted treatment use and OS were compared. Results: The 116 705 patients with PAC were identified: 1320 (9%) AA, 3732 (3%) DCC, 7142 (6%) DA, and 95 511 (82%) PDAC. DA, DCC, and PDAC were associated with worse survival compared with AA (hazard ratio [HR], 1.10; 95% CI, 1.1-1.1; HR, 1.50; 95% CI, 1.4-1.6, and HR, 1.90; 95% CI, 1.8-1.9). Among resected patients, DA was associated with improved survival compared with AA (HR, 0.70; 95% CI, 0.67-0.75); DCC and PDAC were associated with worse survival (HR, 1.41; 95% CI, 1.31-1.53 and HR, 2.041; 95% CI, 1.07-2.12). Resected AA, PDAC, and DA, but not DCC, demonstrated significantly improved survival over the studied period. While all patients had increased adjuvant therapy (AT) receipt over time (P < 0.001), only patients with PDAC had increased neoadjuvant therapy (NAT) receipt (P < 0.001). Conclusion: Resected PDAC, AA, and DA were associated with clinically significant improved survival over time, mirroring a concurrent associated increased receipt of AT.

AB - Background and Objectives: Periampullary adenocarcinoma (PAC) is stratified anatomically: ampullary adenocarcinoma (AA), distal cholangiocarcinoma (DCC), duodenal adenocarcinoma (DA), and pancreatic ductal adenocarcinoma (PDAC). We aimed to determine differences in incidence, prognosis, and treatment in stage-matched PAC patients in a longitudinal study. Methods: PAC patients were identified in The National Cancer Database from 2004 to 2012. Clinicopathological variables were compared between subtypes. Covariate-adjusted treatment use and OS were compared. Results: The 116 705 patients with PAC were identified: 1320 (9%) AA, 3732 (3%) DCC, 7142 (6%) DA, and 95 511 (82%) PDAC. DA, DCC, and PDAC were associated with worse survival compared with AA (hazard ratio [HR], 1.10; 95% CI, 1.1-1.1; HR, 1.50; 95% CI, 1.4-1.6, and HR, 1.90; 95% CI, 1.8-1.9). Among resected patients, DA was associated with improved survival compared with AA (HR, 0.70; 95% CI, 0.67-0.75); DCC and PDAC were associated with worse survival (HR, 1.41; 95% CI, 1.31-1.53 and HR, 2.041; 95% CI, 1.07-2.12). Resected AA, PDAC, and DA, but not DCC, demonstrated significantly improved survival over the studied period. While all patients had increased adjuvant therapy (AT) receipt over time (P < 0.001), only patients with PDAC had increased neoadjuvant therapy (NAT) receipt (P < 0.001). Conclusion: Resected PDAC, AA, and DA were associated with clinically significant improved survival over time, mirroring a concurrent associated increased receipt of AT.

KW - adjuvant therapy

KW - ampullary

KW - distal cholangiocarcionma

KW - duodenal

KW - longitudinal

KW - pancreatic

KW - periampullary

UR - http://www.scopus.com/inward/record.url?scp=85058674840&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058674840&partnerID=8YFLogxK

U2 - 10.1002/jso.25336

DO - 10.1002/jso.25336

M3 - Article

C2 - 30561818

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

ER -